Publications by authors named "Philip Beer"

Claim this Profile
I
Inhibitors of pyrimidine synthesis synergize with N4-hydroxycytidine to diminish influenza virus replication.
Leon Schrell, David Scheibner, Antje Dickmanns, Kim M Stegmann, Lukas Mathias Michaely, Philip Beer

Antiviral Res· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synergistic interference with SARS-CoV-2 replication by molnupiravir-derived N-hydroxycytidine and inhibitors of CTP synthetase in cell culture.
Kim M Stegmann, Antje Dickmanns, Hannah L Fuchs, David Scheibner, Björn-Patrick Mohl, Philip A Beer

Virology· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving outcomes of patients with pancreatic cancer.
Stephan B Dreyer, Philip Beer, Sunil R Hingorani, Andrew V Biankin

Nat Rev Clin Oncol· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined inhibition of CTPS1 and ATR is a metabolic vulnerability in p53-deficient myeloma cells.
Romane Durand, Céline Bellanger, Géraldine Descamps, Christelle Dousset, Sophie Maïga, Philip Beer

Hemasphere· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Selective pharmacologic targeting of CTPS1 shows single-agent activity and synergizes with BCL2 inhibition in aggressive mantle cell lymphoma.
Romane Durand, Céline Bellanger, Charlotte Kervoëlen, Benoit Tessoulin, Christelle Dousset, Philip Beer

Haematologica· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interpreting and integrating genomic tests results in clinical cancer care: Overview and practical guidance.
Raffaella Casolino, Philip A Beer, Debyani Chakravarty, Melissa B Davis, Umberto Malapelle

CA Cancer J Clin· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTPS1 is a novel therapeutic target in multiple myeloma which synergizes with inhibition of CHEK1, ATR or WEE1.
Christina Pfeiffer, Alexander M Grandits, Hélène Asnagli, Anja Schneller, Julia Huber, Philip A Beer

Leukemia· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential roles of CTP synthetases CTPS1 and CTPS2 in cell proliferation.
Norbert Minet, Anne-Claire Boschat, Rebecca Lane, David Laughton, Philip Beer

Life Sci Alliance· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CTP Synthase 1 Is a Novel Therapeutic Target in Lymphoma.
Hélène Asnagli, Norbert Minet, Christina Pfeiffer, Eef Hoeben, Rebecca Lane, Philip A Beer

Hemasphere· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Molecular subclusters of follicular lymphoma: a report from the United Kingdom's Haematological Malignancy Research Network.
Simon Crouch, Daniel Painter, Sharon L Barrans, Eve Roman, Philip A Beer

Blood Adv· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer Biomarkers in the era of precision oncology: Addressing the needs of patients and health systems.
Nicola Normanno, Kathi Apostolidis, Francesco de Lorenzo, Philip A Beer, Raymond Henderson

Semin Cancer Biol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Germline Aberrations in Pancreatic Cancer: Implications for Clinical Care.
Raffaella Casolino, Vincenzo Corbo, Philip Beer, Chang-Il Hwang, Salvatore Paiella

Cancers (Basel)· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and phase I studies of KA2237, a selective and potent inhibitor of PI3K β/δ in relapsed refractory B cell lymphoma.
Loretta J Nastoupil, Sattva S Neelapu, Richard Eric Davis, Felipe Samaniego, Nathan H Fowler, Philip A Beer

Leuk Lymphoma· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genomic characterization of hepatoid tumors: context matters.
Rita T Lawlor, Andrea Mafficini, Concetta Sciammarella, Cinzia Cantù, Borislav C Rusev, Philip A Beer

Hum Pathol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential inverse dysregulation of the RNA helicases DDX3X and DDX3Y facilitates MYC-driven lymphomagenesis.
Chun Gong, Joanna A Krupka, Jie Gao, Nicholas F Grigoropoulos, George Giotopoulos, Philip Beer

Mol Cell· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Homologous Recombination Deficiency in Pancreatic Cancer: A Systematic Review and Prevalence Meta-Analysis.
Raffaella Casolino, Salvatore Paiella, Danila Azzolina, Philip A Beer, Vincenzo Corbo

J Clin Oncol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical Development and First-in-Human Study of KA2507, a Selective and Potent Inhibitor of Histone Deacetylase 6, for Patients with Refractory Solid Tumors.
Apostolia M Tsimberidou, Philip A Beer, Carrie A Cartwright, Cara Haymaker, Henry H Vo

Clin Cancer Res· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression.
Ivan Sloma, Philip Beer, Christophe Desterke, Elizabeth Bulaeva, Misha Bilenky

Haematologica· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of the LymphGen classification tool to 928 clinically and genetically-characterised cases of diffuse large B cell lymphoma (DLBCL).
Hendrik F P Runge, Stuart Lacy, Sharon Barrans, Philip A Beer, Daniel Painter

Br J Haematol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MYC-induced human acute myeloid leukemia requires a continuing IL-3/GM-CSF costimulus.
Elizabeth Bulaeva, Davide Pellacani, Naoto Nakamichi, Colin A Hammond, Philip A Beer

Blood· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Defining the clinical genomic landscape for real-world precision oncology.
Philip A Beer, Susanna L Cooke, David K Chang, Andrew V Biankin

Genomics· November 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report.
Stuart E Lacy, Sharon L Barrans, Philip A Beer, Daniel Painter, Alexandra G Smith

Blood· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assays for functionally defined normal and malignant mammary stem cells.
Syed Mohammed Musheer Aalam, Philip Anthony Beer, Nagarajan Kannan

Adv Cancer Res· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reasons to be testing: the dawn of complex molecular profiling in routine oncology practice.
Philip A Beer, Susanna L Cooke, David K Chang, Andrew V Biankin

Ann Oncol· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Genetic modification of primary human B cells to model high-grade lymphoma.
Rebecca Caeser, Miriam Di Re, Joanna A Krupka, Jie Gao, Maribel Lara-Chica, Philip A Beer

Nat Commun· October 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis